Base de dados : MEDLINE
Pesquisa : D03.132.577.249.562.149.287 [Categoria DeCS]
Referências encontradas : 501 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 51 ir para página                         

  1 / 501 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28448772
[Au] Autor:Tran S; Lavitas P; Stevens K; Greenwood BC; Clements K; Alper CJ; Lenz K; Price M; Hydery T; Arnold JL; Takeshita M; Bacon R; Peristere JP; Jeffrey PL
[Ad] Endereço:1 Clinical Pharmacy Services, University of Massachusetts Medical School, Shrewsbury.
[Ti] Título:The Effect of a Federal Controlled Substance Act Schedule Change on Hydrocodone Combination Products Claims in a Medicaid Population.
[So] Source:J Manag Care Spec Pharm;23(5):532-539, 2017 May.
[Is] ISSN:2376-1032
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: In 2012, hydrocodone combination products (HCPs) were the most prescribed medications in the United States. Under the Controlled Substance Act of 1970, hydrocodone alone was classified as a Schedule II drug, while HCPs were classified as Schedule III, indicating a lower risk for abuse and misuse. However, according to a Drug Enforcement Agency analysis, the addition of nonopioids has not been shown to diminish abuse potential of hydrocodone. In response to concerns for drug abuse and overdose, the Drug Enforcement Agency rescheduled HCPs to Schedule II in October 2014, with the intent of limiting overprescribing and increasing awareness of their abuse potential. However, it is unknown whether this has affected the overall claims for HCPs in a Medicaid population. OBJECTIVES: To (a) compare the trend in HCP prescription claims with select non-HCP (opioid and nonopioid) analgesic claims before and after the HCP schedule change in the Massachusetts Medicaid fee-for-service/Primary Care Clinician plan population and (b) identify if there was a change in HCP new start member and claim characteristics before and after the HCP schedule change. METHODS: This quasi-experimental, retrospective study used enrollment and pharmacy claims data to evaluate all members in the study population 1 year before and after the HCP schedule change. The number of claims for HCPs and select non-HCP analgesics was reported as the monthly rate per total population, and an interrupted time series analysis compared the change in the monthly rate of claims across groups. Members with 1 or more pharmacy claims for a new HCP prescription during a 5-month period before or after the HCP schedule change were analyzed to determine member demographics (age, gender, and number of claims) and claim characteristics (average daily dose, average quantity per claim, and days supply). RESULTS: The rate of HCP claims increased before and decreased after the HCP schedule change. Controlling for the trend during the period before the HCP schedule change, the rate of HCP claims per 1,000 members per month decreased at a greater rate than non-HCP analgesics in the period after the HCP schedule change (P < 0.001). The percentage of HCP claims for new start members decreased after the HCP schedule change (44.9% vs. 34.1% of all HCP claims pre- to post-schedule change; P < 0.001). In the group of new starts, there was not a significant difference in the average daily dose (26.3 mg vs. 26.4 mg; P = 0.69), while there was a decrease in average number of tablets dispensed per claim (from 37.1 to 20.3 tablets; P < 0.001) and an increase in the percentage of claims for a shorter days supply (from 57.7% to 81.6%; P < 0.001). CONCLUSIONS: The findings of this study suggest that the HCP schedule change may have contributed to the decrease in claims for HCPs in a Medicaid population. After the HCP schedule change, there was a trend towards decreased HCP use among new starts. DISCLOSURES: No outside funding supported this study. The authors have nothing to disclose. Study concept and design were contributed by all authors except for Arnold and Clements. Tran, Arnold, and Clements took the lead in data collection, along with Peristere, and data interpretation was performed by all the authors, except Arnold. The manuscript was written primarily by Tran, along with Lavitas, Stevens, and Greenwood, and revised by all the authors except Arnold and Peristere. A poster of this research project was presented at the Academy of Managed Care Pharmacy's 2016 Annual Meeting in San Francisco, California, April 2016.
[Mh] Termos MeSH primário: Analgésicos Opioides/administração & dosagem
Controle de Medicamentos e Entorpecentes/legislação & jurisprudência
Hidrocodona/administração & dosagem
Padrões de Prática Médica/estatística & dados numéricos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Analgésicos Opioides/classificação
Substâncias Controladas/administração & dosagem
Substâncias Controladas/classificação
Combinação de Medicamentos
Feminino
Seres Humanos
Hidrocodona/classificação
Masculino
Medicaid
Meia-Idade
Estudos Retrospectivos
Estados Unidos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Controlled Substances); 0 (Drug Combinations); 6YKS4Y3WQ7 (Hydrocodone)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180111
[Lr] Data última revisão:
180111
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170428
[St] Status:MEDLINE
[do] DOI:10.18553/jmcp.2017.23.5.532


  2 / 501 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28975284
[Au] Autor:Haymond S; Nagpal G; Heiman H
[Ad] Endereço:Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
[Ti] Título:Urine Drug Screens to Monitor Opioid Use for Managing Chronic Pain.
[So] Source:JAMA;318(11):1061-1062, 2017 Sep 19.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Analgésicos Opioides/uso terapêutico
Transtornos Relacionados ao Uso de Cocaína/diagnóstico
Cocaína/urina
Hidrocodona/uso terapêutico
Dor Lombar/tratamento farmacológico
Detecção do Abuso de Substâncias
[Mh] Termos MeSH secundário: Dor Crônica/tratamento farmacológico
Monitoramento de Medicamentos
Feminino
Seres Humanos
Hidrocodona/urina
Imunoensaio
Meia-Idade
Transtornos Relacionados ao Uso de Opioides/diagnóstico
Sensibilidade e Especificidade
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics, Opioid); 6YKS4Y3WQ7 (Hydrocodone); I5Y540LHVR (Cocaine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171005
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.10593


  3 / 501 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28635179
[Au] Autor:Curtis JR; Xie F; Smith C; Saag KG; Chen L; Beukelman T; Mannion M; Yun H; Kertesz S
[Ad] Endereço:University of Alabama at Birmingham.
[Ti] Título:Changing Trends in Opioid Use Among Patients With Rheumatoid Arthritis in the United States.
[So] Source:Arthritis Rheumatol;69(9):1733-1740, 2017 Sep.
[Is] ISSN:2326-5205
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Opioid prescribing recently has come under intense scrutiny. However, longitudinal patterns of prescription opioid receipt in a population-based cohort of patients with chronic pain, such as those with rheumatoid arthritis (RA), have not been well characterized. The aim of this study was to examine both trends over time and variability in individual physician prescribing of short-term and long-term use of opioids. METHODS: We identified a cohort of RA patients based on 2006-2014 Medicare data and evaluated longitudinal time trends in "regular" use of opioids. A separate analysis conducted in 2014 assessed rheumatologist-specific variability in regular use of opioid prescriptions in patients with RA. RESULTS: We identified 97,859 RA patients meeting the eligibility criteria. The mean age of the patients was 67 years, 80% were female, 82% were white, and 12% were African American. The most commonly used opioids were those that combined acetaminophen with hydrocodone or propoxyphene. Regular opioid prescribing increased slowly but peaked in 2010 before propoxyphene was withdrawn from the market. Following the withdrawal of propoxyphene, receipt of hydrocodone and tramadol increased commensurately, and overall opioid use declined only slightly. Factors associated with regular use of opioids included younger age, female sex, African American race, back pain, fibromyalgia, anxiety, and depression. Variability between US rheumatologists (n = 4,024) in prescribing the regular use of opioids for their RA patients was high; in the average rheumatologist's practice, 40% of RA patients used prescription opioids regularly. In almost half of the patients, at least some opioid prescriptions were written by a rheumatologist, and 14% received opioids that were co-prescribed concurrently by more than 1 physician. CONCLUSION: In the US, opioid use in older patients with RA peaked in 2010 and is now declining slightly. Withdrawal of propoxyphene from the US market in 2010 had minimal effect on overall opioid use, because use of propoxyphene was replaced by increased use of other opioids.
[Mh] Termos MeSH primário: Analgésicos Opioides/uso terapêutico
Artrite Reumatoide/tratamento farmacológico
Prescrições de Medicamentos/estatística & dados numéricos
Medicare/estatística & dados numéricos
Padrões de Prática Médica/estatística & dados numéricos
[Mh] Termos MeSH secundário: Acetaminofen/uso terapêutico
Idoso
Analgésicos não Entorpecentes/uso terapêutico
Estudos de Coortes
Dextropropoxifeno/uso terapêutico
Feminino
Seres Humanos
Hidrocodona/uso terapêutico
Masculino
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics, Non-Narcotic); 0 (Analgesics, Opioid); 362O9ITL9D (Acetaminophen); 6YKS4Y3WQ7 (Hydrocodone); S2F83W92TK (Dextropropoxyphene)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170921
[Lr] Data última revisão:
170921
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170622
[St] Status:MEDLINE
[do] DOI:10.1002/art.40152


  4 / 501 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28574523
[Au] Autor:Keesling AD; Wilson M; Wilkins R
[Ad] Endereço:Ark City Clinic, Arkansas City, KS, USA.
[Ti] Título:Neuropathic pain treatment provides unexpected benefit.
[So] Source:J Fam Pract;66(6):388-390, 2017 Jun.
[Is] ISSN:1533-7294
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A 57-year-old African American woman was being treated at our clinic for neurogenic urinary incontinence (UI). The UI, which occurred day and night, began 2 years earlier following a laminectomy of vertebrae C3 to C6 with spinal fusion of C3 to C7 for cervical spinal stenosis. The UI persisted despite physical therapy and trials of oxybutynin and imipramine. Since the surgery, the patient had also been experiencing chronic (debilitating) neuropathic pain in both legs, and the sensation of incomplete bladder emptying. She denied bowel incontinence or saddle anesthesia. Her prescription medications included hydrocodone-acetaminophen 7.5/325 mg every 6 hours as needed for pain and lisinopril 20 mg/d for essential hypertension. The patient's body mass index was 23.3.
[Mh] Termos MeSH primário: Acetaminofen/uso terapêutico
Analgésicos Opioides/uso terapêutico
Hidrocodona/uso terapêutico
Neuralgia/tratamento farmacológico
Neuralgia/etiologia
[Mh] Termos MeSH secundário: Vértebras Cervicais/cirurgia
Combinação de Medicamentos
Feminino
Seres Humanos
Laminectomia/efeitos adversos
Meia-Idade
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Drug Combinations); 0 (acetaminophen, hydrocodone drug combination); 362O9ITL9D (Acetaminophen); 6YKS4Y3WQ7 (Hydrocodone)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170815
[Lr] Data última revisão:
170815
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170603
[St] Status:MEDLINE


  5 / 501 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28442580
[Au] Autor:Jacob JC; Poklis JL; Akbarali HI; Henderson G; Dewey WL
[Ad] Endereço:Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia- (J.C.J., J.L.P., H.I.A., W.L.D.); and School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, United Kingdom (G.H.).
[Ti] Título:Ethanol Reversal of Tolerance to the Antinociceptive Effects of Oxycodone and Hydrocodone.
[So] Source:J Pharmacol Exp Ther;362(1):45-52, 2017 Jul.
[Is] ISSN:1521-0103
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This study compared the development of tolerance to two orally bioavailable prescription opioids, oxycodone and hydrocodone, to that of morphine, and the reversal of this tolerance by ethanol. Oxycodone (s.c.) was significantly more potent in the mouse tail-withdrawal assay than either morphine or hydrocodone. Oxycodone was also significantly more potent in this assay than hydrocodone when administered orally. Tolerance was seen following chronic subcutaneous administration of each of the three drugs and by the chronic administration of oral oxycodone, but not following the chronic oral administration of hydrocodone. Ethanol (1 g/kg i.p.) significantly reversed the tolerance to the subcutaneous administration of each of the three opioids that developed when given 30 minutes prior to challenge doses. It took twice as much ethanol, when given orally, to reverse the tolerance to oxycodone. We investigated whether the observed tolerance to oxycodone and its reversal by ethanol were due to biodispositional changes or reflected a true neuronal tolerance. As expected, a relationship between brain oxycodone concentrations and activity in the tail-immersion test existed following administration of acute oral oxycodone. Following chronic treatment, brain oxycodone concentrations were significantly lower than acute concentrations. Oral ethanol (2 g/kg) reversed the tolerance to chronic oxycodone, but did not alter brain concentrations of either acute or chronic oxycodone. These studies show that there is a metabolic component of tolerance to oxycodone; however, the reversal of that tolerance by ethanol is not due to an alteration of the biodisposition of oxycodone, but rather is neuronal in nature.
[Mh] Termos MeSH primário: Analgésicos Opioides/farmacologia
Depressores do Sistema Nervoso Central/farmacologia
Etanol/farmacologia
Hidrocodona/farmacologia
Oxicodona/farmacologia
[Mh] Termos MeSH secundário: Analgésicos Opioides/farmacocinética
Animais
Comportamento Animal/efeitos dos fármacos
Encéfalo/efeitos dos fármacos
Encéfalo/metabolismo
Relação Dose-Resposta a Droga
Tolerância a Medicamentos
Hidrocodona/farmacocinética
Masculino
Camundongos
Oxicodona/farmacocinética
Dor/psicologia
Medição da Dor/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Central Nervous System Depressants); 3K9958V90M (Ethanol); 6YKS4Y3WQ7 (Hydrocodone); CD35PMG570 (Oxycodone)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170929
[Lr] Data última revisão:
170929
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170427
[St] Status:MEDLINE
[do] DOI:10.1124/jpet.117.241083


  6 / 501 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28292504
[Au] Autor:Varisco TJ; Ogunsanya ME; Barner JC; Fleming ML
[Ti] Título:Pharmacists' perceptions regarding the impact of hydrocodone rescheduling on prescription volume, workflow management, and patient outcomes.
[So] Source:J Am Pharm Assoc (2003);57(2S):S51-S62, 2017 Mar - Apr.
[Is] ISSN:1544-3450
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To determine (1) pharmacists' perceptions of how rescheduling of hydrocodone combination products (HCPs) from Drug Enforcement Agency (DEA) Schedule III to DEA Schedule II has influenced prescription volume and revenue, pharmacy workflow management, and patient outcomes; and (2) whether perceptions differed between pharmacists who support versus those who oppose HCP rescheduling. DESIGN: A cross-sectional mail survey. SETTING: Texas community pharmacies from October to December 2015. PARTICIPANTS: One thousand randomly selected, registered Texas community pharmacists drawn from the Texas State Board of Pharmacy registry. MAIN OUTCOME MEASURES: Pharmacists' perceptions, measured on a 5-point Likert scale of HCP rescheduling and its impact on prescription volume and revenue, workflow management, and patient outcomes. Measures were developed specifically for this study. RESULTS: The response rate was 17% (n = 164). The majority of pharmacists (70.4%) supported HCP rescheduling. More than 80% of respondents perceived that the volume of 2 alternative pain medications-tramadol (DEA Schedule IV) and acetaminophen with codeine (DEA Schedule III) prescriptions dispensed-either "increased" or "significantly increased" (82.0% and 85.8%, respectively) following rescheduling. Overall, pharmacists who opposed rescheduling were significantly more likely to report negative perceptions regarding revenue (P = 0.0142), inventory management (P = 0.0024), and drug shortages (P = 0.0005) than those who supported rescheduling. However, pharmacists who supported rescheduling had more positive perceptions about electronic prescribing (P <0.0115), patient safety (P <0.001), drug abuse (P <0.0001), and legitimate use (P <0.0001). CONCLUSION: Results showed that legislative efforts, such as rescheduling HCPs, influenced pharmacists' perceptions of practice and patient outcomes. Currently, little is known regarding the impact of HCP rescheduling on pharmacy practice. As new laws are passed to address the opioid epidemic in America, more research will be needed to determine whether legislation is an effective means for managing appropriate access to HCPs and other narcotic analgesics.
[Mh] Termos MeSH primário: Analgésicos Opioides/classificação
Serviços Comunitários de Farmácia/organização & administração
Hidrocodona/classificação
Farmacêuticos/organização & administração
[Mh] Termos MeSH secundário: Adulto
Analgésicos Opioides/administração & dosagem
Atitude do Pessoal de Saúde
Substâncias Controladas
Estudos Transversais
Controle de Medicamentos e Entorpecentes
Feminino
Pesquisas sobre Serviços de Saúde
Seres Humanos
Hidrocodona/administração & dosagem
Masculino
Meia-Idade
Farmacêuticos/psicologia
Texas
Fluxo de Trabalho
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Controlled Substances); 6YKS4Y3WQ7 (Hydrocodone)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170904
[Lr] Data última revisão:
170904
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170316
[St] Status:MEDLINE


  7 / 501 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28215574
[Au] Autor:Stewart A; Zborovancik KJ; Stiely KL
[Ti] Título:The impact of pharmacy services on opioid prescribing in dental practice.
[So] Source:J Am Pharm Assoc (2003);57(2S):S78-S82, 2017 Mar - Apr.
[Is] ISSN:1544-3450
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To compare rates of dental opioid prescribing between periods of full and partial integration of pharmacy services and periods of no integration. METHODS: This observational study used a retrospective chart review of opioid prescriptions written by dental providers practicing in a free dental clinic for the medically underserved over a period of 74 months. Pharmacy services were fully integrated into the practice model for 48 of the 74 months under study. During this time frame, all dental opioid orders required review by the pharmacy department before prescribing. Outcomes related to prescribing rates and errors were compared between groups, which were defined by the level of integrated pharmacy services. Demographic and prescription-specific data (drug name, dose, quantity, directions, professional designation of individual entering order) and clinic appointment data were collected and analyzed with the use of descriptive and inferential statistics. RESULTS: A total of 102 opioids were prescribed to 89 patients; hydrocodone-acetaminophen combination products were the most frequently used. Opioid prescribing rates were 5 times greater when pharmacy services were not integrated (P <0.001); and dentists were 81% less likely to prescribe opioids when pharmacy was fully integrated (odds ratio 0.19, 95% confidence interval 0.124-0.293; P <0.001). Frequency of hydrocodone use compared with other opioids did not decrease after the rescheduling of hydrocodone to a Schedule II controlled substance. The frequency of prescribing errors was not statistically different between groups, although there were numerically fewer errors with integrated pharmacy services. CONCLUSION: The literature reports that dentists are the third most frequent prescribers of opioids. The findings from this study suggest that collaboration between pharmacists and dentists has the potential to decrease opioid utilization in primary dental practice.
[Mh] Termos MeSH primário: Analgésicos Opioides/administração & dosagem
Assistência Farmacêutica/organização & administração
Farmacêuticos/organização & administração
Padrões de Prática Odontológica/estatística & dados numéricos
[Mh] Termos MeSH secundário: Acetaminofen/administração & dosagem
Adulto
Idoso
Comportamento Cooperativo
Prestação Integrada de Cuidados de Saúde/organização & administração
Assistência Odontológica/organização & administração
Combinação de Medicamentos
Feminino
Seres Humanos
Hidrocodona/administração & dosagem
Masculino
Área Carente de Assistência Médica
Erros de Medicação/prevenção & controle
Erros de Medicação/estatística & dados numéricos
Meia-Idade
Padrões de Prática Odontológica/normas
Estudos Retrospectivos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Drug Combinations); 0 (acetaminophen, hydrocodone drug combination); 362O9ITL9D (Acetaminophen); 6YKS4Y3WQ7 (Hydrocodone)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170904
[Lr] Data última revisão:
170904
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170221
[St] Status:MEDLINE


  8 / 501 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28103678
[Au] Autor:Kimishima A; Wenthur CJ; Zhou B; Janda KD
[Ad] Endereço:Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Worm Institute for Research and Medicine (WIRM), The Scripps Research Institute , La Jolla, California 92037, United States.
[Ti] Título:An Advance in Prescription Opioid Vaccines: Overdose Mortality Reduction and Extraordinary Alteration of Drug Half-Life.
[So] Source:ACS Chem Biol;12(1):36-40, 2017 01 20.
[Is] ISSN:1554-8937
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Prescription opioids (POs) such as oxycodone and hydrocodone are highly effective medications for pain management, yet they also present a substantial risk for abuse and addiction. The consumption of POs has been escalating worldwide, resulting in tens of thousands of deaths due to overdose each year. Pharmacokinetic strategies based upon vaccination present an attractive avenue to suppress PO abuse. Herein, the preparation of two active PO vaccines is described that were found to elicit high-affinity antiopioid antibodies through a structurally congruent drug-hapten design. Administration of these vaccines resulted in a significant blockade of opioid analgesic activity, along with an unprecedented increase in drug serum half-life and protection against lethal overdose.
[Mh] Termos MeSH primário: Analgésicos Opioides/imunologia
Formação de Anticorpos
Overdose de Drogas/prevenção & controle
Hidrocodona/imunologia
Transtornos Relacionados ao Uso de Opioides/prevenção & controle
Oxicodona/imunologia
Vacinas/imunologia
[Mh] Termos MeSH secundário: Analgésicos Opioides/administração & dosagem
Analgésicos Opioides/sangue
Animais
Overdose de Drogas/sangue
Overdose de Drogas/imunologia
Meia-Vida
Haptenos/administração & dosagem
Haptenos/sangue
Haptenos/imunologia
Seres Humanos
Hidrocodona/administração & dosagem
Hidrocodona/sangue
Camundongos
Transtornos Relacionados ao Uso de Opioides/sangue
Transtornos Relacionados ao Uso de Opioides/imunologia
Oxicodona/administração & dosagem
Oxicodona/sangue
Toxoide Tetânico/administração & dosagem
Toxoide Tetânico/sangue
Toxoide Tetânico/imunologia
Vacinação
Vacinas/administração & dosagem
Vacinas/sangue
[Pt] Tipo de publicação:LETTER; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Haptens); 0 (Tetanus Toxoid); 0 (Vaccines); 6YKS4Y3WQ7 (Hydrocodone); CD35PMG570 (Oxycodone)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170222
[Lr] Data última revisão:
170222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170121
[St] Status:MEDLINE
[do] DOI:10.1021/acschembio.6b00977


  9 / 501 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Registro de Ensaios Clínicos
[PMID]:28072811
[Au] Autor:Campbell K; Kutz JW; Shoup A; Wen W; Lynch SY; He E; Ripa SR
[Ad] Endereço:Audiology Consultant, Glenarm, IL.
[Ti] Título:Evaluation of the Ototoxicity Potential of Once-Daily, Single-Entity Hydrocodone in Patients with Chronic Pain: Results of Two Phase-3 Clinical Studies.
[So] Source:Pain Physician;20(1):E183-E193, 2017 Jan-Feb.
[Is] ISSN:2150-1149
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Use/misuse of the opioid combination hydrocodone-acetaminophen has been associated with permanent hearing loss. Although reports have been rare, this potential effect can have significant detrimental effect on patients' overall quality of life. To date, the ototoxic effect of hydrocodone alone has not been systematically investigated. OBJECTIVE: In this report, we aimed to evaluate the potential ototoxicity of a novel, single-entity, once-daily, extended-release hydrocodone tablet (Hysingla® ER; HYD). STUDY DESIGN: Clinical study. SETTING: Audiology clinics in US. METHODS: Results from 1207 patients in two phase 3 clinical studies were evaluated: A placebo-controlled study with an enriched enrollment, randomized withdrawal design in patients with chronic low back pain, and an open-label, long-term, safety study in patients with chronic nonmalignant and non-neuropathic pain. Comprehensive audiologic assessments (comprising pure-tone air-conduction audiometry in the conventional [0.25-8 kHz] and ultra-high [10-16 kHz] frequencies, pure-tone bone-conduction audiometry, tympanometry, speech reception thresholds, and word recognition) were conducted at baseline and end-of-studies; air-conduction audiometry was conducted periodically during the studies. All audiologic assessments were performed in audiology clinics in the United States by licensed audiologists. The primary endpoint was changes from baseline in pure-tone air-conduction thresholds in the conventional frequencies during the studies. These trials are registered with ClinicalTrials.gov, identifiers NCT01400139 and NCT01452529. RESULTS: During the studies, mean changes from baseline in air-conduction thresholds were clinically unremarkable. Bidirectional variability across all test frequencies was observed; 82% of patients did not experience significant threshold changes during the studies, 7% had potential hearing decrement, and 10% experienced hearing sensitivity improvement. No notable differences were observed between patients receiving HYD and placebo or between different HYD doses. CONCLUSION: No ototoxic signal was observed for single-entity hydrocodone tablets at the dosages and treatment durations investigated. Key words: Audiologic monitoring, clinical trials, hydrocodone, opioids, ototoxicity monitoring, sensorineural hearing loss.
[Mh] Termos MeSH primário: Analgésicos Opioides
Dor Crônica/tratamento farmacológico
Hidrocodona
Dor Lombar/tratamento farmacológico
[Mh] Termos MeSH secundário: Analgésicos Opioides/administração & dosagem
Analgésicos Opioides/uso terapêutico
Dor Crônica/psicologia
Seres Humanos
Hidrocodona/administração & dosagem
Hidrocodona/uso terapêutico
Dor Lombar/psicologia
Qualidade de Vida
[Pt] Tipo de publicação:CLINICAL STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics, Opioid); 6YKS4Y3WQ7 (Hydrocodone)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170721
[Lr] Data última revisão:
170721
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170111
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE


  10 / 501 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27983881
[Au] Autor:Taber L; Baldridge S; He E; Ripa SR
[Ad] Endereço:a Arizona Research Center , Phoenix , AZ , USA.
[Ti] Título:Hysingla® ER, a once-daily, single-entity hydrocodone with abuse-deterrent properties in treating chronic nonmalignant and nonneuropathic pain in patients with osteoarthritis.
[So] Source:Postgrad Med;129(1):133-139, 2017 Jan.
[Is] ISSN:1941-9260
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Osteoarthritis (OA)-related chronic pain is associated with physical and psychosocial impairment as well as poorer quality of life. There is limited literature on long-term opioid therapy in OA patients. This post hoc analysis of OA patients assessed the long-term safety and effectiveness of a once-daily, single-entity, extended-release formulation of hydrocodone (HYD) with abuse-deterrent properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which other treatment options are inadequate. METHODS: This is a post hoc analysis of the 307 patients with OA pain from a primary open-label study. Following screening and dose titration, patients who achieved a stable HYD dose continued into a 52-week maintenance period. Supplemental non-opioid or short-acting opioid analgesics were allowed throughout the study. Safety was monitored. Effectiveness evaluations included "average pain over the last 24 hours" scores, "pain right now" scores, Brief Pain Inventory-Short Form and treatment satisfaction questionnaire. RESULTS: No new or unexpected safety concerns emerged during treatment with HYD. HYD demonstrated a safety profile consistent with other µ-opioid agonists with 22% discontinuations of treatment due to adverse events, a majority of which were related to the study drug. Clinically meaningful analgesia was achieved as mean "average pain over the last 24 hours"; scores decreased by 2.9 points from baseline to the end of maintenance. During the maintenance period, pain severity declined 2.7 points and interference by 2.5 points from baseline. Mean "pain right now" scores were similar at dosing and 12 hours later. A majority of patients reported satisfaction with HYD. CONCLUSION: In OA patients, long-term HYD treatment was generally well tolerated and provided clinically important analgesia.
[Mh] Termos MeSH primário: Analgésicos Opioides/uso terapêutico
Química Farmacêutica
Dor Crônica/tratamento farmacológico
Preparações de Ação Retardada/uso terapêutico
Hidrocodona/uso terapêutico
Osteoartrite/tratamento farmacológico
Uso Indevido de Medicamentos sob Prescrição/prevenção & controle
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Feminino
Seres Humanos
Masculino
Meia-Idade
Estados Unidos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Delayed-Action Preparations); 6YKS4Y3WQ7 (Hydrocodone)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170206
[Lr] Data última revisão:
170206
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161217
[St] Status:MEDLINE
[do] DOI:10.1080/00325481.2017.1274224



página 1 de 51 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde